Regional screening network for characterization of the molecular epidemiology of non-small cell lung cancer (NSCLC) and implementation of personalized treatment
| Autor: | Khosro Hekmat, Monika Serke, Lukas C. Heukamp, Erich Stoelben, Thomas Zander, Christian Mattonet, Walburga Engel-Riedel, Ulrich Gerigk, Marc Bos, Konrad Frank, Reinhard Buettner, Marcel Reiser, Stephan Schmitz, Andreas Schlesinger, Sabine Merkelbach-Bruse, Michael Brockmann, Juergen Wolf, Holger Schulz, Yon-Dschun Ko, Jana Fassunke |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Oncology
medicine.medical_specialty Cancer Research Molecular screening Molecular epidemiology business.industry Personalized treatment non-small cell lung cancer (NSCLC) Cancer medicine.disease Bioinformatics Molecular diagnostics medicine.disease_cause Internal medicine medicine Adenocarcinoma KRAS business neoplasms |
| Zdroj: | Journal of Clinical Oncology. 30:CRA10529-CRA10529 |
| ISSN: | 1527-7755 0732-183X |
| Popis: | CRA10529 Background: Personalized treatment of genetically stratified subgroups has the potential to substantially improve outcome in NSCLC. A major challenge now is to implement high-quality molecular diagnostics and personalized treatment strategies in routine clinical practice also outside of highly specialized academic centers. Methods: We have established a molecular screening network in the catchment area of our comprehensive cancer center encompassing about 2.5 million inhabitants in March 2010 after review of the local ethics committee (10-242). Lung adenocarcinoma (AD) was screened centrally for ALK translocations, mutations in KRAS, EGFR, BRAF and PIK3CA and for amplification of ERBB2. Squamous cell carcinoma (SQ) was analyzed for FGFR1 amplifications. Results: 2032 NSCLC samples were acquired of which 1782 in the Cologne-Bonn area indicating a capture rate of 60-70% of all NSCLC samples in the area. Material was suitable for molecular analysis in 77%. Distribution of histological subtypes was as expected (AD 63.4%, SQ 26.7, large cell carcinoma 1.4%, adenosquamous cell carcinoma 1.8%, carcinoid 0.1%, NSCLC NOS 6.7%. In AD the following frequencies of genetic lesions were detected: KRAS (32%), EGFR (13%), ALK (3%), BRAF (2%), PIK3CA (2%), ERBB2 (2%). EGFR mutations were highly enriched in the lepidic and micropapillary subtype of AD (30-32%), whereas the solid subtype only harboured a very small amount of the tested oncogenic lesions. In SQ FGFR1 amplification was detected in 78/500. Overall 40% of all NSCLC samples harboured potentially tractable oncogenic lesions. All patients with ALK translocations received crizotinib when clinically indicated. 75% of the stage IIIB/IV patients with activating EGFR mutations received EGFR-TKI treatment. In addition, clinical trials have been initiated to provide personalized treatment options to all patients with tractable genetic lesions. Conclusions: High-quality molecular diagnostics and identification of patients for personalized treatment approaches is feasible in daily clinical routine for the majority of diagnostic samples also in a non-academic setting. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|